InvestorsHub Logo
Followers 9
Posts 750
Boards Moderated 0
Alias Born 10/19/2008

Re: None

Saturday, 03/01/2014 2:30:43 PM

Saturday, March 01, 2014 2:30:43 PM

Post# of 146238
According to Official Company News Releases

NNVC has renewed a contract with independent researcher Dr. Eva Harris, a world expert in Dengue Fever and other infecteous diseases. Dr. Harris is reported to have an excellent mouse model of dengue virus infection and disease.

NNVC Company used this recognized expert in the world to evaluate its anti-dengue agents. In those studies, the their treatment produced a high level of effectiveness. In Prof. Harris’ model of dengue vascular leak, dengue virus infection of the laboratory mouse strain, AG129, is 100% fatal when the mice are untreated. In contrast, in the same study, animals treated with one of NanoViricides' anti-dengue agents achieved an unprecedented 50% survival rate!

I anticipate extended studies will further demonstrate DengueCide effectiveness in the treatment of Dengue Fever.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News